Ozempic's (GLP-1) depravity is worse than COVID vaccines - 2025
Summary of book chapter - 2026
- Ozempic (semaglutide) works by paralyzing the stomach so food cannot be digested properly. Obesity is not an Ozempic deficiency, and drugging the fish instead of cleaning the tank is the whole error.
- Novo Nordisk, the drug's Danish manufacturer, became Europe's most valuable company. The industry corrupts doctors, medical societies, journals, research, and the news that covers it.
- Side effects include stomach paralysis, vision loss, and an EU investigation into suicidal ideation. Many patients cannot tolerate the drug, and weight returns when they stop taking it.
- If Ozempic were funded for the 80 percent of American adults who are overweight, the annual cost could approach a trillion dollars to manage a symptom rather than address its cause.
- Everything predicted about Ozempic has come true. We are watching a pharmaceutical disaster unfold in real time, fully aware of the pattern.
Yoho preface
This interview was recorded about a year ago, but nearly every word remains valuable. Since then, the predictions have proven disturbingly accurate. Ozempic has been approved for expanded use and is now widely reimbursed by insurers. The pharmaceutical industry has created a system in which every major institution—medical schools, research organizations, professional societies, the media, and even civil rights groups—profits when Americans get sick and stay sick. These companies pay doctors directly to prescribe their products, fund research claiming their drugs work, control medical education that teaches doctors what to prescribe, and buy off the news media that should be investigating these practices.
The result is that 80 percent of American adults are overweight or obese, diabetes and prediabetes rates continue to climb, and the proposed solution is a drug that costs $20,000 per year, must be taken for life, causes severe gastrointestinal problems in many patients, and doesn’t address the root cause. The fact that this drug was fast-tracked for government funding while metabolic disease continues to worsen reveals the moral bankruptcy of the system.
Introduction
With grateful thanks to Tucker Carlson and Mr. Means, here is their interview, edited for readability.
Obesity is not an Ozempic deficiency. This simple fact exposes the fundamental corruption at the heart of the pharmaceutical industry’s latest blockbuster drug. When 80 percent of American adults are overweight or obese because of environmental factors—subsidized junk food, corrupted dietary guidelines, and a food system designed to addict—the answer is not a $20,000-per-year injectable drug that must be taken for life. . . . .
Dr. Yoho wrapup
As of December 2025, nearly 3,000 lawsuits have been filed and consolidated into multidistrict litigation in federal court in Pennsylvania. These lawsuits allege serious gastrointestinal injuries, including gastroparesis, intestinal blockages, and ileus. Since this interview, the FDA has updated Ozempic’s warning label multiple times—adding warnings for ileus in September 2023, severe gastrointestinal adverse reactions in January 2025, and pulmonary aspiration during anesthesia in November 2024.
Multiple studies published in 2024 and 2025 have linked semaglutide use to irreversible blindness from non-arteritic anterior ischemic optic neuropathy (NAION). The World Health Organization issued a warning about this risk in June 2025. Hundreds of patients have filed lawsuits.
Research published in January 2025 revealed additional concerning side effects beyond those discussed in this interview. The study found increased risks of kidney stones, arthritis, fainting, and drug-induced pancreatitis among patients using GLP-1 drugs. Nearly 40 percent of hypoglycemia cases and 15 percent of gastrointestinal cases required hospitalization. Studies have also linked GLP-1 drugs to reduced bone density when used without exercise, raising concerns about long-term musculoskeletal health.
The prediction that this would become “the highest-funded drug from the US taxpayer in history” is also coming true. We’re conducting a mass experiment in metabolic intervention using a lifetime drug that paralyzes digestive function. The 5- year data is already alarming; the 20-year data doesn’t exist yet